Admescope Briefly
ADME-Tox expert, with a top-notch knowledge in drug metabolism, drug-drug-interactions & quantitative bioanalysis. From screening assays to highly tailored studies.
Symeres Finland Oy is a Finnish ADME-Tox contract research company founded in 2011, operating under Admescope brand. Straight from the beginning, Admescope’s growth has been exponential and today Admescope is managed by a team with a strong background in the CRO business.
Since 2020, Admescope has been a part of Symeres, with the ability to provide medicinal chemistry and integrated drug discovery & development services through the Symeres organization.
The Admescope team consists of chemists, biochemists, pharmacologists and technicians, all with extensive experience and strong expertise in ADME studies. Admescope serves customers in >30 different countries on five continents, having planned and conducted a high number of ADME-related studies for biotech and big pharma companies.
Our continuous service development and ability to adapt customers’ in-house processes has a lot to do with our outstanding customer satisfaction rates. Performing beyond our customers’ needs and expectations is important to us therefore we invest a lot of time, money and effort into R&D.
The aim of our R&D activities is to strengthen our position in the market and further improve our expertise and skill set, as well as being able provide even more innovative and efficient ways to conduct studies and produce top quality data for our customers.
Frequently Asked Questions
Admescope is a specialist ADME-Tox and DMPK contract research organization based in Finland. Since 2020, Admescope has been part of Symeres, combining deep ADME-Tox expertise with access to integrated drug discovery, development, manufacturing, and regulatory capabilities.
Admescope specializes in ADME-Tox services, including drug metabolism, DMPK, drug-drug interactions, quantitative bioanalysis, permeability and transporter studies, in vitro toxicology, safety metabolism, and tailored ADME study design.
Admescope works with biotech, pharmaceutical, and drug discovery teams worldwide. We support customers in more than 30 countries, from early-stage screening through to preclinical development and complex tailored study programs.
Yes. Admescope offers both established screening assays and highly tailored studies. Our scientific team can adapt study design, experimental conditions, reporting format, and data interpretation to match your compounds, project requirements, and internal workflows.
Admescope provides scientific consultation alongside study delivery. Our team helps clients interpret results, combine findings across multiple studies, and make informed decisions throughout drug discovery and preclinical development.
Yes. As part of Symeres, Admescope can support integrated programs that combine ADME-Tox and DMPK studies with medicinal chemistry, biology, development, manufacturing, and regulatory expertise, helping projects progress more efficiently.
